


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**UPGRADE TO AA IN MSCI ESG RATINGS**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, with its systematic layout, persistent development, and outstanding practices in terms of environmental, social, and governance (ESG), the Group has been upgraded from A to AA in Morgan Stanley Capital International (MSCI) ESG Ratings, thus positioning the Group as a remarkable leader in ESG practices among major pharmaceutical companies around the world.

The Group has established and continued to optimize the system of its ESG governance, with the Board as the highest decision-making body. Centering around the core ESG strategy called “CARE”, which stands for “Cure, Accessible, Relationship, and Environmental”, the Group systematically initiated its ESG-specific practices to precisely advance the deep integration of sustainability-based philosophy with corporate decision-making and business operations.

In respect of environmental-friendly achievements, the Group has proactively responded to the “30·60” dual carbon goals in the country and continued to deeply integrate the concept of green development into all stages of operation. As a green enterprise within the pharmaceutical industry in China that pioneers to announce its target mapping towards carbon neutrality, the Group has proactively advanced specialized attempts to improve energy-saving and emission-reduction technologies. Over the past five consecutive years, the emission intensity of multiple major pollutants has continued to decline by more than 10% annually. Meanwhile, the Group has systematically deployed its initiatives targeting low-carbon transformation, including the expansion of green energy and the establishment of low-carbon culture. In 2025, the Group realised the simultaneous reduction in carbon emission intensity and total emissions for the first time, which marked a robust step towards the milestone goal of “carbon peak”. To date, the sustained efforts of the Group in green development have been widely recognised, with three subsidiaries being awarded the nation-level title of “Green Factory”.

When it comes to social responsibilities, the Group earnestly upholds its operational philosophy of “science for a healthier world”. As guided by international innovation strategies, the Group proactively drives its business upgrades, fills clinical gaps, and provides robust protection for the health-based rights of more patients. In recent years, the investment in research and development (R&D) made by the Group has continued to rise, with cumulative R&D expenditures exceeding RMB13 billion over the past three years. Meanwhile, the Group has established an international R&D platform and carried out a series of precision investments and acquisitions, including the full acquisition of LaNova Medicines Limited (“**LaNova Medicines**”), Hangzhou Hygieia Biomedical Co., Ltd. (“**Hygieia**”), and other innovative drug companies, thereby expanding its innovative pipeline and upgrading its technological platforms. In early 2026, the Group entered into an exclusive licensing agreement with Sanofi S.A. regarding rovadicitinib, thus further facilitating high-quality pharmaceutical achievements to benefit patients worldwide. Over the past three years, the key products of the Group have cumulatively served over 160 million patients.

The Group attaches great importance to the building and development of talent teams. Centering around its talent development strategies, the Group systematically implements the “Employee Assistance Program (EAP)” and specialized initiatives of talent development in order to promote the growth of the enterprise together with its employees.

While continuously optimizing its own sustainability capabilities, the Group has proactively engaged in exercises on charity and public welfare. Over the past three years, it has made cumulative donations of over RMB150 million, with focuses on, among others, disaster relief, poverty alleviation, rural revitalization, and affordable healthcare. Through these concrete actions, the Group has given back to society and reflected its commitment to corporate social responsibility.

The upgrade to the rating of AA represents the high recognition from MSCI for the ESG management standard and practical effectiveness of the Group and the significant milestone of the Group in fulfilling sustainable development and corporate social responsibilities, thereby setting a benchmark for high-quality and sustainable development among enterprises engaged in innovative drugs in China. As a leading company within the innovative drug industry in China, the Group unwaveringly believes that outstanding ESG performance is the cornerstone for creating long-term value and achieving high-quality development of enterprises. Looking ahead, the Group will continue to deepen its initiatives across the three dimensions of environmental, social, and governance, while leveraging its industry leadership to drive the synergistic development across the supply chain, promote the green and high-quality development of the pharmaceutical and healthcare industry in China, create sustainable and shared value for all stakeholders, and steadily head for becoming the industry benchmark for the worldwide ESG.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 23 March 2026

*As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*